|
|
 |

Formulary
Exceptional Access Program (EAP)
The Individual Clinical Review process is being phased out and a more streamlined Exceptional Access Program (EAP) has been created to handle requests for drugs that are not listed in the Formulary. For more information please visit the EAP section.
Drug Benefit Prices (DBPs) for products reimbursed under the EAP
Pursuant to section 15 of O.Reg. 201/96 made under the Ontario Drug Benefit Act (ODBA), the Executive Officer (EO) has entered into agreements with manufacturers to establish Drug Benefit Prices (DBPs) for products reimbursed under the Exceptional Access Program (EAP).
For the following products reimbursed under the EAP, the Health Network System (HNS) will adjudicate claims at the DBP listed below.
| DIN |
Trade Name |
Strength |
Dosage Form |
DBP |
| Effective date : October 8, 2009 |
| 02169649 |
Betaseron |
0.3mg/Vial |
Injection |
$110.0000 |
| Effective date : September 21, 2009 |
| 02286386 |
Tysabri |
300mg/15mL vial |
Inj Sol-15mL Vial Pk |
$2,809.1900 |
| Effective date : July 22, 2009 |
| 02317699 |
Revlimid |
15mg |
Cap |
$382.0000 |
| 02317710 |
Revlimid |
25mg |
Cap |
$424.0000 |
| Effective date : June 11, 2009 |
| 02284863 |
Myozyme |
50mg/vial |
Lyophylized Powder |
$840.3100 |
| Effective date : June 1, 2009 |
| 02241112 |
Avandia |
2mg |
Tab |
$1.3755 |
| 02241113 |
Avandia |
4mg |
Tab |
$2.1584 |
| 02241114 |
Avandia |
8mg |
Tab |
$3.0866 |
| Effective date : May 27, 2009 |
| 02296314 |
Elaprase |
2mg/mL |
3mL Vial |
$3,800.00 |
| Effective date : May 20, 2009 |
| 02258595 |
Humira |
40mg/0.8mL |
Inj Pref Syr |
$707.2200 |
| 09857294 |
Humira |
40mg/0.8mL |
Inj Pref Pen |
$707.2200 |
| Effective Date : April 29, 2009 |
| 02287420 |
Exjade |
125mg |
Tablet for Suspension |
$9.8750 |
| 02287439 |
Exjade |
250mg |
Tablet for Suspension |
$19.7500 |
| 02287447 |
Exjade |
500mg |
Tablet for Suspension |
$39.5000 |
| Effective Date : January 19, 2009 |
| 02304899 |
Revlimid |
5mg |
Capsule |
$340.0000 |
| 02304902 |
Revlimid |
10mg |
Capsule |
$361.0000 |
| Effective Date : December 3, 2008 |
| 2274728 |
Enbrel |
50mg/mL |
Inj Pref Syr |
$364.2800 |
| Effective Date : November 17, 2008 |
| 02284227 |
Nexavar |
200mg |
Tablet |
$45.0625 |
| Effective Date : October 31, 2008 |
| 02282097 |
Orencia |
250mg/15mL Vial |
Injection |
$440.0000 |
| Effective Date : May 30, 2008 |
| 02280795 |
Sutent |
12.5mg |
Capsule |
$62.0357 |
| 02280809 |
Sutent |
25mg |
Capsule |
$124.0711 |
| 02280817 |
Sutent |
50mg |
Capsule |
$248.1425 |
Until further notice, for all other products reimbursed under the EAP, pharmacists will continue to be reimbursed their acquisition cost plus the applicable markup (currently 8%).
|